Results 81 to 90 of about 975,813 (425)

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’) [PDF]

ZD1839 (‘Iressa’) is an orally active, selective epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR–TKI), which blocks signal transduction pathways implicated in proliferation and survival of cancer cells, and other host-dependent processes
Dubreuil, A, Fischel, J L, Formento, P, Laurent-Puig, P, Magné, N, Milano, G, Poupon, M-F   +6 more
core   +2 more sources

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium [PDF]

, 2014
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standardized
Ali, H Raza, Benitez, Javier, Blomqvist, Carl, Blows, Fiona M, Bolla, Manjeet K, Brinton, Louise, Brock, Ian W, Broeks, Annegien, Brook, Mark N, Caldas, Carlos, Couch, Fergus J, Coulson, Penny, Cox, Angela, Cross, Simon S, Daley, Frances, Dawson, Sarah-Jane, Devillee, Peter, Easton, Douglas F, Fagerholm, Rainer, Figueroa, Jonine, García-Closas, Montserrat, Gazinska, Patrycja, Heikkilä, Päivi, Hollestelle, Antoinette, Howat, William J, Johnson, Nicola, Jones, Louise, Kataja, Vesa, Kosma, Veli-Matti, Lissowska, Jolanta, Mannermaa, Arto, McDuffus, Leigh-Anne, Menéndez, Primitiva, Mesker, Wilma E, Miller, Jodi, Morris, Lorna, Nevanlinna, Heli, Olson, Janet E, Perez, Jose Ignacio Arias, Pharoah, Paul D, Pinder, Sarah, Provenzano, Elena, Reed, Malcolm W, Sanders, Joyce, Sawyer, Elinor J, Schmidt, Marjanka K, Seyaneve, Caroline M, Sherman, Mark E, Sironen, Reijo, van Deurzen, Carolien H M, Visscher, Daniel, Wesseling, Jelle   +51 more
core   +5 more sources

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Homologous Control of Protein Signaling Networks [PDF]

Journal of Theoretical Biology 279 (2011) 29-43, 2010
In a previous paper we introduced a method called augmented sparse reconstruction (ASR) that identifies links among nodes of ordinary differential equation networks, given a small set of observed trajectories with various initial conditions. The main purpose of that technique was to reconstruct intracellular protein signaling networks. In this paper we
arxiv   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors

Tumor Biology, 2017
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are first-choice treatments for advanced non-small-cell lung cancer patients harboring EGFR mutations.
Huang-Chih Chang, Yu-Mu Chen, Chia-Cheng Tseng, Kuo-Tung Huang, Chin-Chou Wang, Yung-Che Chen, Chien-Hao Lai, Wen-Feng Fang, Hsu-Ching Kao, Meng-Chih Lin   +9 more
doaj   +1 more source

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death [PDF]

, 2017
Although inhibition of the epidermal growth factor receptor is a plausible therapy for malignant gliomas that, in vitro, enhances apoptosis, the results of clinical trials have been disappointing.
Brucker, Daniel P., Burger, Michael C., Rieger, Johannes, Ronellenfitsch, Michael W., Steinbach, Joachim P., Tritschler, Felix, Weller, Michael, Wick, Wolfgang, Wolking, Stefan   +8 more
core  

Coexistence of three EGFR mutations in an NSCLC patient: A brief report [PDF]

, 2018
The epidermal growth factor receptor (EGFR) represents a molecular target for tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC) patients with a mutation in the EGFR gene. Mutations of the EGFR gene that occur at a single position in NSCLC
Belardinilli, Francesca, Coppa, Anna, Ferraro, Sergio, Gelibter, Alain, Giannini, Giuseppe, Gradilone, Angela, Nicolazzo, Chiara, Occhipinti, Mario, Zani, Massimo   +8 more
core   +1 more source

Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease.

Physiological Reviews, 2016
The epidermal growth factor receptor (EGFR) is the prototypical member of a family of membrane-associated intrinsic tyrosine kinase receptors, the ErbB family.
Jianchun Chen, Fenghua Zeng, Steven J Forrester, S. Eguchi, Ming-Zhi Zhang, Raymond C. Harris   +5 more
semanticscholar   +1 more source

On‐treatment dynamics of circulating extracellular vesicles in the first‐line setting of patients with advanced non‐small cell lung cancer: the LEXOVE prospective study

Molecular Oncology, EarlyView.
The LEXOVE prospective study evaluated plasma cell‐free extracellular vesicle (cfEV) dynamics using Bradford assay and dynamic light scattering in metastatic non‐small cell lung cancer patients undergoing first‐line treatments, correlating a ∆cfEV < 20% with improved median progression‐free survival in responders versus non‐responders.
Valerio Gristina, Viviana Bazan, Nadia Barraco, Simona Taverna, Mauro Manno, Samuele Raccosta, Anna Paola Carreca, Marco Bono, Tancredi Didier Bazan Russo, Francesco Pepe, Pasquale Pisapia, Lorena Incorvaia, Giuseppe Badalamenti, Giancarlo Troncone, Umberto Malapelle, Daniele Santini, Antonio Russo, Antonio Galvano   +17 more
wiley   +1 more source